In the LIVE trial, liraglutide treatment resulted in no change in left ventricular systolic function, whereas liraglutide related to an increase in heart rate and more serious cardiac adverse events among chronic heart failure patients with and without type 2 diabetes [45]
Originally developed for treating type 2 diabetes, it has shown an unexpected but beneficial side effect: significant weight loss
Unbiased proteomic screen for binding proteins to modified lysines on histone H3
Emerging and Approved Therapeutic Peptides: Mechanisms, Clinical Uses, Safety Profiles, and Regulatory Status Across Health Conditions Abstract Therapeutic peptides represent a rapidly growing class of pharmaceutical agents that bridge the gap between small molecule drugs and large protein therapeutics
To view a copy of this licence, visit About this article Cite this article Oliveira, K.C., Marcos, C.M., Penteado, L.d.A